drugset / Trial / NCT03907826
PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.
Timeline
- Start
- 2020-03-01
- Primary completion
- 2026-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |
| Background | Cisplatin | Other / unclassified | 80 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |